Ubs Group Ag Taysha Gene Therapies, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 421,396 shares of TSHA stock, worth $678,447. This represents 0.0% of its overall portfolio holdings.

Number of Shares

421,396

Previous 92,001 358.03%

Holding current value

$678,447

Previous $184,000 296.2%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.27 - $3.24 $418,331 - $1.07 Million	329,395 Added 358.03%	421,396 $729,000
Q3 2024 Nov 14, 2024	BUY	$2.01 - $2.46 $72,203 - $88,368	35,922 Added 64.06%	92,001 $184,000
Q2 2024 Aug 13, 2024	SELL	$2.04 - $4.17 $271,738 - $555,464	-133,205 Reduced 70.37%	56,079 $125,000
Q1 2024 May 13, 2024	BUY	$1.43 - $3.25 $265,037 - $602,358	185,341 Added 4700.51%	189,284 $543,000
Q4 2023 Feb 09, 2024	BUY	$1.33 - $2.88 $4,512 - $9,771	3,393 Added 616.91%	3,943 $6,000
Q3 2023 Nov 09, 2023	SELL	$0.63 - $3.66 $4,636 - $26,933	-7,359 Reduced 93.05%	550 $1,000
Q2 2023 Aug 11, 2023	BUY	$0.59 - $0.87 $2,571 - $3,792	4,359 Added 122.79%	7,909 $5,000
Q1 2023 May 12, 2023	SELL	$0.65 - $2.3 $128,884 - $456,053	-198,284 Reduced 98.24%	3,550 $2,000
Q4 2022 Feb 08, 2023	BUY	$1.39 - $2.98 $271,831 - $582,774	195,562 Added 3118.02%	201,834 $456,000
Q3 2022 Nov 10, 2022	SELL	$1.76 - $4.94 $155,386 - $436,142	-88,288 Reduced 93.37%	6,272 $12,000
Q2 2022 Aug 10, 2022	BUY	$2.47 - $6.77 $65,652 - $179,946	26,580 Added 39.1%	94,560 $352,000
Q1 2022 May 16, 2022	BUY	$5.22 - $11.86 $88,447 - $200,955	16,944 Added 33.2%	67,980 $443,000
Q4 2021 Feb 14, 2022	BUY	$11.43 - $19.2 $201,773 - $338,937	17,653 Added 52.88%	51,036 $594,000
Q3 2021 Nov 15, 2021	BUY	$15.82 - $21.57 $444,273 - $605,750	28,083 Added 529.87%	33,383 $622,000
Q2 2021 Aug 13, 2021	SELL	$19.29 - $26.38 $596,273 - $815,432	-30,911 Reduced 85.36%	5,300 $112,000
Q1 2021 May 12, 2021	BUY	$20.3 - $31.75 $9,378 - $14,668	462 Added 1.29%	36,211 $735,000
Q4 2020 Feb 11, 2021	BUY	$19.14 - $28.13 $473,695 - $696,189	24,749 Added 224.99%	35,749 $949,000
Q3 2020 Nov 12, 2020	BUY	$22.4 - $24.47 $246,399 - $269,170	11,000 New	11,000 $247,000

Others Institutions Holding TSHA

# of Institutions

130

Shares Held

151M

Call Options Held

48K

Put Options Held

7.8K

View Full List

About Taysha Gene Therapies, Inc.

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $77.9M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

More about TSHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account